Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Qiu, Shuwei ^a,b   Lin, Sheng ^c   Hu, Dan ^b,d   Feng, Yimin ^b   Tan, Yang ^b   Peng, Ying ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b East Tennessee State University   (United States)

^c Shenzhen Research Institute of Population and Family Planning   (China)

^d RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Glioblastoma multiforme; Interaction; microRNA; Overall survival; Prognostic marker; Progression free survival

Indexed keywords

MICRORNA; MICRORNA 130A; MICRORNA 155; MICRORNA 210; MICRORNA 323; MICRORNA 326; MICRORNA 329; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; BIOINFORMATICS; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; GENDER; GLIOBLASTOMA; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RNA ANALYSIS;

BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; MICRORNAS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84872050193     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-10     Document Type: Article

References (40)

1. Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol 2010, 12:520-527. 10.1093/neuonc/nop066, 2940648, 20511189.
2. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110. 10.1016/j.ccr.2009.12.020, 2818769, 20129251.
3. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522. 10.1016/j.ccr.2010.03.017, 2872684, 20399149.
4. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 2010, 11:252-263.
5. Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res 2010, 70:7027-7030. 10.1158/0008-5472.CAN-10-2010, 2940943, 20807816.
6. Zhi F, Chen X, Wang S, Xia X, Shi Y, Guan W, Shao N, Qu H, Yang C, Zhang Y, et al. The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer 2010, 46:1640-1649. 10.1016/j.ejca.2010.02.003, 20219352.
7. Delfino KR, Serao NV, Southey BR, Rodriguez-Zas SL. Therapy-, gender- and race-specific microRNA markers, target genes and networks related to glioblastoma recurrence and survival. Cancer Genomics Proteomics 2011, 8:173-183. 3321577, 21737610.
8. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838. 10.1038/nature03702, 15944708.
9. TCGA Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. 10.1038/nature07385, 2671642, 18772890, TCGA.
10. Gabriely G, Yi M, Narayan RS, Niers JM, Wurdinger T, Imitola J, Ligon KL, Kesari S, Esau C, Stephens RM, et al. Human glioma growth is controlled by microRNA-10b. Cancer Res 2011, 71:3563-3572. 10.1158/0008-5472.CAN-10-3568, 3096675, 21471404.
11. Consortium TGO Gene ontology: tool for the unification of biology. Nat Genet 2000, 25:25-29. 10.1038/75556, 3037419, 10802651, Consortium TGO.
12. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000, 28:27-30. 10.1093/nar/28.1.27, 102409, 10592173.
13. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:92-105. 2612969, 18955434.
14. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.
15. Martin A, Ochagavia ME, Rabasa LC, Miranda J, Fernandez-de-Cossio J, Bringas R. BisoGenet: a new tool for gene network building, visualization and analysis. BMC Bioinformatics 2010, 11:91. 10.1186/1471-2105-11-91, 3098113, 20163717.
16. Vlachos IS, Kostoulas N, Vergoulis T, Georgakilas G, Reczko M, Maragkakis M, Paraskevopoulou MD, Prionidis K, Dalamagas T, Hatzigeorgiou AG. DIANA miRPath v. 2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res 2012, 40:W498-504. 10.1093/nar/gks494, 3394305, 22649059.
17. Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 2009, 37:D105-110. 10.1093/nar/gkn851, 2686554, 18996891.
18. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007, 129:1401-1414. 10.1016/j.cell.2007.04.040, 2681231, 17604727.
19. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF, et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 2008, 6:14. 10.1186/1741-7015-6-14, 2443372, 18577219.
20. Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, Rouhanifard SH, Sohn-Lee C, le Sage C, Agami R, Tuschl T, Holland EC. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 2009, 23:1327-1337. 10.1101/gad.1777409, 2701585, 19487573.
21. Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stuhler K, Meyer HE, Reifenberger G. Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 2009, 20:539-550.
22. Zhou X, Ren Y, Moore L, Mei M, You Y, Xu P, Wang B, Wang G, Jia Z, Pu P, et al. Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest 2010, 90:144-155. 10.1038/labinvest.2009.126, 20048743.
23. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812. 10.1126/science.1164382, 2820389, 18772396.
24. Camara-Quintana JQ, Nitta RT, Li G. Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT. Neurosurg Clin N Am 2012, 23:237-246. 10.1016/j.nec.2012.01.011, 22440867.
25. Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani L, Heppner FL, et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol 2012,
26. von Deimling A, Korshunov A, Hartmann C. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 2011, 21:74-87. 10.1111/j.1750-3639.2010.00454.x, 21129061.
27. Motomura K, Natsume A, Watanabe R, Ito I, Kato Y, Momota H, Nishikawa R, Mishima K, Nakasu Y, Abe T, et al. Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas. Cancer Sci 2012,
28. Zinn PO, Sathyan P, Mahajan B, Bruyere J, Hegi M, Majumder S, Colen RR. A Novel Volume-Age-KPS (VAK) Glioblastoma Classification Identifies a Prognostic Cognate microRNA-Gene Signature. PLoS One 2012, 7:e41522. 10.1371/journal.pone.0041522, 3411674, 22870228.
29. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. microRNAs in cancer management. Lancet Oncol 2012, 13:e249-258. 10.1016/S1470-2045(12)70073-6, 22652233.
30. Osman A. MicroRNAs in health and disease-basic science and clinical applications. Clin Lab 2012, 58:393-402.
31. Corsini LR, Bronte G, Terrasi M, Amodeo V, Fanale D, Fiorentino E, Cicero G, Bazan V, Russo A. The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opin Ther Targets 2012, 16(Suppl 2):S103-109.
32. Lakomy R, Sana J, Hankeova S, Fadrus P, Kren L, Lzicarova E, Svoboda M, Dolezelova H, Smrcka M, Vyzula R, et al. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci 2011, 102:2186-2190. 10.1111/j.1349-7006.2011.02092.x, 21895872.
33. Srinivasan S, Patric IR, Somasundaram K. A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One 2011, 6:e17438. 10.1371/journal.pone.0017438, 3069027, 21483847.
34. Kefas B, Comeau L, Floyd DH, Seleverstov O, Godlewski J, Schmittgen T, Jiang J, diPierro CG, Li Y, Chiocca EA, et al. The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J Neurosci 2009, 29:15161-15168. 10.1523/JNEUROSCI.4966-09.2009, 2823067, 19955368.
35. Poltronieri P, D'Urso PI, Mezzolla V, D'Urso OF. Potential of anti-cancer therapy based on anti-miR-155 oligonucleotides in glioma and brain tumours. Chem Biol Drug Des 2012,
36. Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. PLoS Biol 2005, 3:e85. 10.1371/journal.pbio.0030085, 1043860, 15723116.
37. Monticone M, Daga A, Candiani S, Romeo F, Mirisola V, Viaggi S, Melloni I, Pedemonte S, Zona G, Giaretti W, et al. Identification of a novel set of genes reflecting different in vivo invasive patterns of human GBM cells. BMC Cancer 2012, 12:358. 10.1186/1471-2407-12-358, 3502598, 22901239.
38. Xu N, Shen C, Luo Y, Xia L, Xue F, Xia Q, Zhang J. Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem Biophys Res Commun 2012, 425:468-472. 10.1016/j.bbrc.2012.07.127, 22846564.
39. Acunzo M, Visone R, Romano G, Veronese A, Lovat F, Palmieri D, Bottoni A, Garofalo M, Gasparini P, Condorelli G, et al. miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene 2012, 31:634-642.
40. Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell 2012, 149:515-524. 10.1016/j.cell.2012.04.005, 22541426.